Free Trial
→ Crypto Income (almost instantly) (From Awesomely, LLC) (Ad)
NASDAQ:KA

Kineta 3/21/2024 Earnings Report

Kineta logo
Profile

Kineta EPS Results

Actual EPS
-$0.19
Consensus EPS
-$0.29
Beat/Miss
Beat by +$0.10
One Year Ago EPS
N/A

Kineta Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Kineta Announcement Details

Quarter
Date
3/21/2024
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Kineta Earnings Headlines

SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Kineta, Inc. - KANT
December 12, 2024  |  prnewswire.comhttps://www.prnewswire.com/news-releases/shareholder-alert-the-ma-class-action-firm-investigates-the-merger-of-kineta-inc--kant-302330717.html
Kineta and TuHURA Enter Acquisition Agreement
November 25, 2024  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/kineta-and-tuhura-enter-acquisition-agreement?utm_source=marketbeat.com&utm_medium=referral
$100 Trillion “AI Metal” Found in American Ghost Town
Jeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could be the biggest technology story of this decade. In short, he believes what he's holding in his hand is the key to the $100 trillion AI boom… And only one company here in the U.S. can mine this obscure metal.
 |  Brownstone Research (Ad)
Kineta Announces Completion of Enrollment in the Monotherapy Arm of the VISTA-101 Phase 1 Clinical Study in Advanced Solid Tumors
October 18, 2024  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/KA-Q/pressreleases/28938958/kineta-announces-completion-of-enrollment-in-the-monotherapy-arm-of-the-vista-101-phase-1-clinical-study-in-advanced-solid-tumors/
Kineta Announces KVA12123 Abstract Accepted for Poster Presentation at Society for Immunotherapy of Cancer (SITC) 2024
October 4, 2024  |  globenewswire.comhttps://www.globenewswire.com/news-release/2024/10/04/2958356/0/en/kineta-announces-kva12123-abstract-accepted-for-poster-presentation-at-society-for-immunotherapy-of-cancer-sitc-2024.html
Kineta Announces the Extension of the TuHURA Biosciences Exclusivity and Right of First Offer Agreement for KVA12123, Kineta's VISTA blocking antibody Currently in Phase 1
October 2, 2024  |  globenewswire.comhttps://www.globenewswire.com/news-release/2024/10/02/2957342/0/en/kineta-announces-the-extension-of-the-tuhura-biosciences-exclusivity-and-right-of-first-offer-agreement-for-kva12123-kineta-s-vista-blocking-antibody-currently-in-phase-1.html
See More Kineta Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Kineta? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Kineta and other key companies, straight to your email.

About Kineta

Kineta (NASDAQ:KA) is a clinical-stage biotechnology company with a focus on developing immunotherapies that transform patients' lives. It focuses on developing potentially differentiated immunotherapies that address the challenges with current cancer therapy. The company's immuno-oncology pipeline includes KVA12123, a VISTA blocking immunotherapy in development as a twice weekly monoclonal antibody (mAb) infusion drug. KVA12123 is being evaluated in a Phase 1/2 clinical trial as a monotherapy and in combination with pembrolizumab in patients with advanced solid tumors, including non-small cell lung, ovarian, renal cell carcinoma, head and neck, renal cell, and colorectal cancers. It is also developing anti-CD27 agonist mAb immunotherapy to address the problem of exhausted T cells. The company has collaboration and license agreements with MSD International Business GmbH, Genentech, Inc., FAIR Therapeutics B.V., and GigaGen, Inc. Kineta, Inc. is headquartered in Seattle, Washington.

View Kineta Profile

More Earnings Resources from MarketBeat

Earnings Tools
Earnings By Country
Latest Articles